CORDIS - EU research results
CORDIS

Controlled Organoids transplantation as enabler for regenerative medicine translation

Project description

Organ 3D printing for liver regenerative medicine

Liver diseases account for 2 million deaths worldwide every year. While liver transplantation is the most effective way to restore normal functions for various diseases including acute liver failure or liver malignancies, less than 10 % of global transplantation needs are currently met. This EU-funded ORGANTRANS project aims to replace liver transplantation for end-stage liver failure patients through the development of a liver tissue 3D printing platform. The project will cover the entire development cycle from cell source and tissue engineering through the trials allowing for early adoption of its results in clinical practice. Importantly, this research will create novel technologies that can be applied to other organ systems in regenerative medicine.

Objective

End-stage liver failure is a major healthcare challenge. Liver diseases account for approximately 2 million deaths per year worldwide. Liver transplantation is the most effective way to re-establish a liver with normal functions for various diseases including acute liver failure or liver malignancies. Currently, less than 10% of global transplantation needs are met and the gap between patients on transplant waiting lists and available donor organs is steadily increasing.
ORGANTRANS proposes a disruptive alternative to donor organs for patients with chronic or end-stage liver diseases who have still to isolate autologous liver stem cells. Driven by a need of leading European transplant centers, ORGANTRANS will tackle current obstacles for liver regenerative medicine by combining advanced know-how in cell biology, biomaterials, bioengineering, automation, standardization and clinical translation.
ORGANTRANS will develop a liver tissue printing platform that will be shortly deployed under the “compassionate use exemption” by three leading European transplant centers belonging to the consortium or the External Advisory Board. ORGANTRANS will not only deliver an ATMP, but also platform technologies that can be scaled to other organ systems, as organoid technology is one of the largest parts of regenerative medicine. The project covers the entire value chain (from cell source, tissue engineering, bioprinting, post-processing to testing) allowing for early adoption of its results (product & process) in clinical practice. The platform will first be scaled to Europe and then to the rest of the world.

Call for proposal

H2020-SC1-BHC-2018-2020

See other projects for this call

Sub call

H2020-SC1-2019-Single-Stage-RTD

Coordinator

CSEM CENTRE SUISSE D'ELECTRONIQUE ET DE MICROTECHNIQUE SA - RECHERCHE ET DEVELOPPEMENT
Net EU contribution
€ 1 172 441,25
Address
RUE JAQUET DROZ 1
2000 Neuchatel
Switzerland

See on map

Region
Schweiz/Suisse/Svizzera Espace Mittelland Neuchâtel
Activity type
Research Organisations
Links
Total cost
€ 1 172 441,25

Participants (7)